Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (DE:GE9)
BERLIN:GE9
Holding DE:GE9?
Track your performance easily
GE9 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€203.80 - €304.00
Previous Close€212.5
Volume0.00
Average Volume (3M)10.00
Market Cap
€14.04B
Enterprise Value€10.37B
Total Cash (Recent Filing)kr28.14B
Total Debt (Recent Filing)kr770.00M
Price to Earnings (P/E)22.1
Beta0.39
Next Earnings
Feb 12, 2025EPS Estimate
€3.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.64
Shares Outstanding65,691,573
10 Day Avg. Volume0
30 Day Avg. Volume10
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.17
Price to Sales (P/S)0.10
Price to Cash Flow (P/CF)0.90
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€332.36Price Target Upside56.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Genmab A/S News
Bulls Say, Bears Say
Bulls Say
Product Launch SuccessEpkinly launch is progressing, with Genmab specifically highlighting strong Japan launch.
Revenue GrowthGenmab remains very comfortable in continued Darzalex revenue growth, with 1L penetration continuing to increase and share in 2L stable.
Strategic PartnershipsThe deal gives Genmab worldwide rights to ProfoundBio’s novel ADC technology platforms and several preclinical and clinical candidates, most notably rinatabart sesutecan (Rina-S).
Bears Say
EarningsThere is significant downside to 2025 and 2026 EBIT forecasts, with increasing operating expenses not yet captured.
Market ExpectationsConsensus margins look overly optimistic, not fully capturing future increasing operating expenses from assets moving into Phase III and higher cost of goods sold.
Product DevelopmentUncertainty around JNJ’s opt-in decision on HexabodyCD38, given limited data and lengthy development timelines, could lead to a double-digit share-price move.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
15.07% Mutual Funds
0.03% Other Institutional Investors
75.09% Public Companies and
Individual Investors
GE9 FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was €203.80 and its highest was €304.00 in the past 12 months.
What is Genmab A/S’s market cap?
Currently, no data Available
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 12, 2025 which is in 94 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 06, 2024. The company reported €2.656 earnings per share for the quarter, missing the consensus estimate of €2.815 by -€0.158.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is €3.33.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 66,176,834 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of €2.656 in its last earnings report, missing expectations of €2.815. Following the earnings report the stock price went up 1.067%.
Which hedge fund is a major shareholder of Genmab A/S?
Currently, no hedge funds are holding shares in DE:GE9
---
Genmab A/S Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€332.36 (56.40% Upside)
€332.36 (56.40% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.96%
12-Months-Change
Fundamentals
Return on Equity
14.72%
Trailing 12-Months
Asset Growth
12.55%
Trailing 12-Months
Company Description
Genmab A/S
Genmab is a Copenhagen-based cancer drug developer, best known for its antibody technology platforms, DuoBody and HexaBody, and multiple myeloma drug Darzalex (daratumumab), which is partnered with Johnson & Johnson. The company also has several pipeline candidates targeting other oncologic indications and autoimmune diseases.
---
GE9 Stock 12 Month Forecast
Average Price Target
€332.36
▲(56.40% Upside)
Technical Analysis
Best Analysts Covering GE9
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
+5.64%
reiterated a buy rating 2 months ago
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +5.64% per trade.
---